retatrutide phase 2 trial obesity triple agonist for diabetes type hormone receptor metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide is gaining attention in – retatrutide clinical trial outcomes The – Triple receptor agonist retatrutide demonstrates

doi: 10.3389/fnbeh.2019.00123 188 OrtegaMAAlvarez-MonMAGarca-MonteroCFraile-MartinezOGuijarroLGLaheraGet al

These medications mimic a hormone naturally produced in your body that helps regulate appetite and blood sugar

A mild deficiency may not cause any symptoms

[14] [15] Some clinicians recommend starting with macrogol or a bulk-forming laxative and adding a stimulant only if needed

When ovulation does occur, it's unpredictable

The trial involving 18,000 people not yet published as of September 2023 is apparently the first to show that GLP-1 drugs can confer heart health benefits for people who are overweight but don't have diabetes